Address correspondence and reprint requests to Dr. T. P. Bleck at Department of Neurology, Box 394, University of Virginia, Charlottesville, VA 22908, U.S.A. E-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Summary: Purpose: To explore outcome differences between propofol and midazolam (MDL) therapy for refractory status epilepticus (RSE).

Methods: Retrospective chart review of consecutive patients treated for RSE between 1995 and 1999.

Results: We found 14 patients treated primarily with propofol and six with MDL. Propofol and MDL therapy achieved 64 and 67% complete clinical seizure suppression, and 78 and 67% electrographic seizure suppression, respectively. Overall mortality, although not statistically significant, was higher with propofol (57%) than with MDL (17%) (p = 0.16). Subgroup mortality data in propofol and MDL patients based on APACHE II (Acute Physiology and Chronic Health Evaluation) score did not show statistically significant differences except for propofol-treated patients with APACHE II score ≥20, who had a higher mortality (p = 0.05). Reclassifying the one patient treated with both agents to the MDL group eliminated this statistically significant difference (p = 0.22).

Conclusions: In our small sample of RSE patients, propofol and MDL did not differ in clinical and electrographic seizure control. Seizure control and overall survival rates, with the goal of electrographic seizure elimination or burst suppression rather than latter alone, were similar to previous reports. In RSE patients with APACHE II score ≥20, survival with MDL may be better than with propofol. A large multicenter, prospective, randomized comparison is needed to clarify these data. If comparable efficacy of these agents in seizure control is borne out, tolerance with regard to hemodynamic compromise, complications, and mortality may dictate the choice of RSE agents.

REFERENCES

1 Working Group on Status Epilepticus. Treatment of convulsive status epilepticus: recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270: 854–9.
PubMed Google Scholar
2 Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39: 18–26.
10.1111/j.1528-1157.1998.tb01269.x
CAS PubMed Web of Science® Google Scholar
3 Lowenstein DH, Aminoff MJ, Simon RP. Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients. Neurology 1988; 38: 395–400.
10.1212/WNL.38.3.395
PubMed Web of Science® Google Scholar
4 Yaffe K & Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993; 43: 895–900.
10.1212/WNL.43.5.895
PubMed Web of Science® Google Scholar
5 Rashkin MC, Youngs C, Penovich P. Pentobarbital treatment of refractory status epilepticus. Neurology 1987; 37: 500–3.
10.1212/WNL.37.3.500
PubMed Web of Science® Google Scholar
6 Towne AR, Pellock JM, Ko D, et al. Determinants of mortality in status epilepticus. Epilepsia 1994; 35: 27–34.
10.1111/j.1528-1157.1994.tb02908.x
CAS PubMed Web of Science® Google Scholar
7 Jagoda A & Riggio S. Refractory status epilepticus in adults. Ann Emerg Med 1993; 22: 1337–48.
10.1016/S0196-0644(05)80120-9
PubMed Web of Science® Google Scholar
8 Campostrini R, Bati MB, Giorgi C, et al. Propofol in the treatment of convulsive status epilepticus: a report of four cases. Nuova Riv Neurol 1991; 1: 176–9.
Google Scholar
9 Natale E, Mattaliano A, Alia G, et al. Propofol treatment of status epilepticus: report of four cases successfully treated. Epilepsia 1993; 34(suppl 2): 124–5.
Google Scholar
10 Exil G, Clancy RR, Hyder DJ. Propofol treatment of refractory status epilepticus: a report of five pediatric cases. Epilepsia 1995; 36(suppl 4): 124.
Google Scholar
11 Cortina J, Ancillo P, Duarte J, et al. Intravenous midazolam suppression of complex partial status refractory to intravenous phenytoin and diazepam. Clin Neuropharmacol 1993; 16: 468–70.
10.1097/00002826-199310000-00013
PubMed Web of Science® Google Scholar
12 Kumar A & Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992; 20: 483–8.
10.1097/00003246-199204000-00009
PubMed Web of Science® Google Scholar
13 Bleck TP. Advances in the management of refractory status epilepticus. Crit Care Med 1993; 21: 955–7.
10.1097/00003246-199307000-00004
PubMed Web of Science® Google Scholar
14 Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. In: S Shorvon, ed. Emergency treatment of status epilepticus. Cambridge, MA: Cambridge University Press, 1994; 175–292.
10.1017/CBO9780511526930.006
Google Scholar
15 Yanny HF & Christmas D. Propofol infusions for status epilepticus [Letter]. Anesthesia 1988; 43: 514.
10.1111/j.1365-2044.1988.tb06658.x
PubMed Web of Science® Google Scholar
16 Wood PR, Browne GPR, Pugh S. Propofol infusion for the treatment of status epilepticus. Lancet 1988; 1: 480–1.
10.1016/S0140-6736(88)91281-0
PubMed Web of Science® Google Scholar
17 Chilvers CR & Laurie PS. Successful use of propofol in status epilepticus. Anesthesia 1990; 45: 995–6.
10.1111/j.1365-2044.1990.tb14664.x
CAS PubMed Web of Science® Google Scholar
18 Mackenzie SJ, Kapadia F, Grant IS. Propofol infusion for control of status epilepticus. Anesthesia 1990; 45: 1043–5.
10.1111/j.1365-2044.1990.tb14884.x
PubMed Web of Science® Google Scholar
19 Alia G, Natale E, Mattaliano A, et al. On two cases of status epilepticus treated with propofol [Abstract]. Epilepsia 1991; 32(suppl 1): 77.
PubMed Web of Science® Google Scholar
20 Borgeat A & Wilder-Smith OH, et al. Propofol in the management of status epilepticus: a case report. Intens Care Med 1994; 20: 148–9.
10.1007/BF01707672
CAS PubMed Web of Science® Google Scholar
21 Pitt-Miller PL, Elcock BJ, Maharaj M. The management of status epilepticus with a continuous propofol infusion. Anesth Analg 1994; 78: 1193–4.
10.1213/00000539-199406000-00033
PubMed Web of Science® Google Scholar
22 Hantson P, VanBrandt N, Verbeeck R, et al. Propofol for refractory status epilepticus. Intens Care Med 1994; 20: 611–2.
10.1007/BF01705733
PubMed Web of Science® Google Scholar
23 Merigan KS, Browning RG, Leeper KV. Successful treatment of amoxapine-induced refractory status epilepticus with propofol (Diprivan). Acad Emerg Med 1995; 2: 128–33.
10.1111/j.1553-2712.1995.tb03177.x
CAS PubMed Web of Science® Google Scholar
24 DeKrom MC, Verduin N, Visser E, et al. Status epilepticus during vigabatrin treatment: a report of three cases. Seizure 1995; 4: 159–62.
10.1016/S1059-1311(95)80099-9
CAS PubMed Web of Science® Google Scholar
25 Harrison AM, Lugo RA, Schunk JE. Treatment of convulsive status epilepticus with propofol: case report. Pediatr Emerg Care 1997; 13: 420–2.
10.1097/00006565-199712000-00019
CAS PubMed Web of Science® Google Scholar
26 Galdames PD, Silva-Rosas C, Aguilera L. Treatment of status epilepticus with midazolam: report of four cases. Neurologia 1994; 9: 109–11.
PubMed Google Scholar
27 Crisp CB, Gannon R, Knauft F. Continuous infusion of midazolam hydrochloride to control status epilepticus. Clin Pharm 1988; 7: 322–4.
PubMed Web of Science® Google Scholar
28 Parent JM & Lowenstein DH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994; 44: 1837–40.
10.1212/WNL.44.10.1837
PubMed Web of Science® Google Scholar
29 Fountain NB & Adams RE. Midazolam treatment of acute and refractory status epilepticus. Clin Neuropharmacol 1999; 22: 261–7.
CAS PubMed Web of Science® Google Scholar
30 Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–28.
10.1097/00003246-198510000-00009
CAS PubMed Web of Science® Google Scholar
31 Treiman DM. Generalized convulsive status epilepticus in adults. Epilepsia 1993; 34(suppl): S2–11.
10.1111/j.1528-1157.1993.tb05902.x
PubMed Web of Science® Google Scholar
32 Lothman EW, Bertram EH, Bekenstein JW, et al. Self-sustaining limbic status epilepticus induced by “continuous hippocampal stimulation”: electrographic and behavioral characteristics. Epilepsy Res 1989; 3: 107–19.
10.1016/0920-1211(89)90038-7
PubMed Web of Science® Google Scholar
33 Lowenstein DH, Simon R, Sharp F. The induction of 72-kDa heat shock protein-like immunoreactivity in the rat brain following flurothyl-induced status epilepticus. Brain Res 1990; 531: 173–82.
10.1016/0006-8993(90)90771-3
CAS PubMed Web of Science® Google Scholar
34 Shimosaka S, So Y, Simon R. Distribution of HSP72 induction and neuronal death following limbic seizures. Neurosci Lett 1992; 138: 202–6.
10.1016/0304-3940(92)90915-T
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume42, Issue3

March 2001

Pages 380-386

Propofol and Midazolam in the Treatment of Refractory Status Epilepticus

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Propofol and Midazolam in the Treatment of Refractory Status Epilepticus

Abstract

REFERENCES

Citing Literature

References

Related

Information